Celldex Therapeutics (CLDX) rallies the day after releasing favorable data from a Phase I/II...

|About: Celldex Therapeutics, Inc (CLDX)|By:, SA News Editor

Celldex Therapeutics (CLDX) rallies the day after releasing favorable data from a Phase I/II study for its cancer treatment DDX-1401. Celldex is testing the therapy for the treatment of such cancers as melanoma. CLDX +12.2% premarket. (PR)